Rezolute, Inc. Board of Directors

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Mr. Nevan Charles Elam J.D.

Mr. Nevan Charles Elam J.D.

Founder, CEO, Principal Financial Officer & Acting Chairman of the Board

Dr. Raj Agrawal M.D.

Dr. Raj Agrawal M.D.

VP & Head of Ophthalmological Clinical Development

Dr. Davelyn Eaves Hood M.B.A., M.D.

Dr. Davelyn Eaves Hood M.B.A., M.D.

Director and Head of Scientific & Patient Affairs

Ms. Erin O'Boyle

Ms. Erin O'Boyle

Senior VP & Head of Clinical Operations

Mr. Michael R. Deperro

Mr. Michael R. Deperro

Senior VP & Head of Corporate Development

Ms. Robyn Sweinhart

Ms. Robyn Sweinhart

VP & Head of Quality

Mr. Chris Milks

Mr. Chris Milks

VP & Head of Finance

Mr. Michael Covarrubias

Mr. Michael Covarrubias

Senior VP & Head of Program & Portfolio Management

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.